Advances of mrna vaccine in tumor: a maze of opportunities and challenges

HIGHLIGHTS

• who: Yuan Yuan from the CEA-specific humoral immunity was observed in all involved patientsFor patients with stage IV cancer, year survival was, %, (95% CI, % to, %). For patients with stage III cancer (n=12), the, year RFS was, %, (95%CI, % to, %) have published the Article: Advances of mRNA vaccine in tumor: a maze of opportunities and challenges, in the Journal: (JOURNAL)
• what: In this review the authors systematically summarized the classification and characteristics of antigens the general process and methods for screening neoantigens the strategies of vaccine preparations and advances in clinical trials as well . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.